PMLiVE5d
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
AOL1mon
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
Novo Nordisk (NYSE: NVO) just made a partnership play worth $600 million with a small biotech called NanoVation that might just change the stock's trajectory for many years to come. On Sept.
PMLiVE8d
Novo Nordisk’s GLP-1 drug semaglutide shows promise in fatty liver disease MASH
The reesults come less than two months after Novo entered into a multi-year partnership worth $600m with NanoVation Therapeutics to advance genetic medicines for cardiometabolic and rare diseases. The ...
Business Wire13d
PopVax Announces 1.15 Million USD in Funding from the Bill & Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...
Asian News International12d
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. "We at PopVax are ...